Wuhan Hvsen Biotechnology Co.,Ltd.

Wuhan Hvsen Biotechnology Co., Ltd. (hereinafter referred to as "HVSEN BIOTECH") was established in 2002 with a registered capital of 166 million Yuan. It is a national high-tech enterprise focusing on the field of animal health. On 24 August 2020, HVSEN BIOTECH was officially listed on gem of Shenzhen Stock Exchange (stock code: 300871). According to the Veterinary Drug Industry Development Report (2020 year) released by China Veterinary Drug Association, HVSEN BIOTECH sales ranked top 5 in the field of veterinary preparations in China.

At present, HVSEN BIOTECH has been accepted 74 patent applications, 48 patents have been authorized, and 11 national new veterinary drug certificates have been obtained, including 6 new veterinary drugs of class II and 4 new veterinary drugs of class III. At present, the R&D department covers 6 specialties including synthetic research, traditional Chinese medicine research, pet special preparation research, veterinary new preparation research, microbial research and analytical research. HVSEN BIOTECH has the CNAS Center and the "HVSEN Research Institute" which is jointly built with Huazhong Agricultural University.

HVSEN BIOTECH has comprehensive supply chain from API to preparation including the business scope on swine, poultry, ruminate, aquatic and pet. Its wholly-owned subsidiary company Hubei Hvsen Biotechnology Co., Ltd., established in 2009, the total investment is nearly 1.5 billion Yuan, it is well-known for the fine quality of Tylvalosin tartrate. HVSEN BIOTECH international trade export to more than 15 countries in South American, Middle East, Southeast Asia, South Asia and etc.